Adoptive CAR T Cell Immunotherapy
618 views | +0 today
Follow
Your new post is loading...
Your new post is loading...
Scooped by Julien Valton
Scoop.it!

A Multidrug Resistant Engineered Car T Cell For Allogeneic Combination Immunotherapy Poster

A Multidrug Resistant Engineered Car T Cell For Allogeneic Combination Immunotherapy Poster | Adoptive CAR T Cell Immunotherapy | Scoop.it
A Multidrug Resistant Engineered Car T Cell For Allogeneic Combination Immunotherapy Poster
more...
No comment yet.
Scooped by Julien Valton
Scoop.it!

Targeted Genome Modifications For Improved Adoptive T Cell Immunotherapy

Targeted Genome Modifications For Improved Adoptive T Cell Immunotherapy | Adoptive CAR T Cell Immunotherapy | Scoop.it
Targeted genome modifications for improved adoptive T-Cell immunotherapy Laurent Poirot, Alexandre Juillerat, Julien Valton, Anne-Sophie Gautron and Philippe Duchateau CELLECTIS SA, 8 rue de la Croix Jarry, 75013 Paris, France.
more...
No comment yet.
Scooped by Julien Valton
Scoop.it!

Cytokine-Induced Killer (CIK) cells engineered with exogenous T cel... - PubMed - NCBI

Hum Gene Ther. 2015 Mar 10. [Epub ahead of print]
more...
No comment yet.
Scooped by Julien Valton
Scoop.it!

DAP12-Based Activating Chimeric Antigen Receptor for NK Cell Tumor Immunotherapy

RT @celltherapynews: DAP12-Based Activating Chimeric Antigen Receptor for NK Cell Tumor Immunotherapy http://t.co/Z1EA76YpjL
more...
No comment yet.
Scooped by Julien Valton
Scoop.it!

CAR-T cells inflict sequential killing of multiple tumor target cells

Adoptive therapy with chimeric antigen receptor (CAR) T cells shows great promise clinically.
more...
No comment yet.
Scooped by Julien Valton
Scoop.it!

Chimeric Antigen Receptors With Mutated IgG4 Fc Spacer Avoid Fc Receptor Binding and Improve T Cell Persistence and Antitumor Efficacy

Chimeric Antigen Receptors With Mutated IgG4 Fc Spacer Avoid Fc Receptor Binding and Improve T Cell Persistence and Antitumor Efficacy Molecular Therapy advance online publication, February 17 2015.
more...
No comment yet.
Scooped by Julien Valton
Scoop.it!

Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model

Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model Gene Therapy advance online publication, February 5 2015.
more...
No comment yet.
Scooped by Julien Valton
Scoop.it!

Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic

Highlights •The presence of immune infiltrate in tumors has been correlated with a good prognosis following treatment.•Tumor-infiltrating lymphocytes have been utilized for the treatment of melanoma.•To broaden this therapy for other cancers, T cells have been genetically modified with either a T cell receptor or a chimeric antigen receptor.•Potential hurdles and novel strategies will be discussed for realizing the full potential of adoptive immunotherapy becoming a standard of care treatment for cancer.
more...
No comment yet.
Scooped by Julien Valton
Scoop.it!

Designing chimeric antigen receptors to effectively and safely target tumors

REVIEW | Designing Chimeric Antigen Receptors to Effectively and Safely Target Tumors #Immunotherapy http://t.co/VdrlbuXb5w Highlights •Description of structural elements of chimeric antigen receptors used to engineer T cells.•Differences between T cell receptor and chimeric antigen receptor recognition.•Types of T cells that can be engineered to target tumor cells.•Strategies for augmenting function and selectivity of chimeric antigen receptors.•Strategies for improving safety of chimeric antigen receptor modified T cells.
more...
No comment yet.
Scooped by Julien Valton
Scoop.it!

Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells

more...
No comment yet.
Scooped by Julien Valton
Scoop.it!

Target Antigen Density Governs the Efficacy of Anti–CD20-CD28-CD3 ζ Chimeric Antigen Receptor–Modified Effector CD8+ T Cells

more...
No comment yet.
Scooped by Julien Valton
Scoop.it!

Targeting CD20+ Aggressive B-Cell Non-Hodgkin Lymphoma by Anti-CD20 CAR mRNA Modified Expanded Natural Killer Cells in vitro and in NSG Mice

The prognosis is very dismal for patients with relapsed CD20+ B-cell non-Hodgkin lymphoma (B-NHL).
more...
No comment yet.
Scooped by Julien Valton
Scoop.it!

CD19 chimeric antigen receptor T cell therapy for haematological malignancies. - PubMed - NCBI

CD19 chimeric antigen receptor T cell therapy for haematological malignancies. - PubMed - NCBI | Adoptive CAR T Cell Immunotherapy | Scoop.it
Br J Haematol. 2015 May;169(4):463-78. doi: 10.1111/bjh.13340. Epub 2015 Mar 5. Research Support, Non-U.S. Gov't; Review
more...
No comment yet.
Scooped by Julien Valton
Scoop.it!

Adenovirus improves the efficacy of adoptive T-cell therapy by recruiting immune cells to and promoting their activity at the tumor

Despite the rapid progress in the development of novel adoptive T-cell therapies, the clinical benefits in treatment of established tumors have remained modest.
more...
No comment yet.
Scooped by Julien Valton
Scoop.it!

Chimeric antigen receptor therapy for cancer. - PubMed - NCBI

Annu Rev Med. 2014;65:333-47. doi: 10.1146/annurev-med-060512-150254. Epub 2013 Nov 20. Review
more...
No comment yet.
Scooped by Julien Valton
Scoop.it!

Identification of Chimeric Antigen Receptors That Mediate Constitutive or Inducible Proliferation of T Cells

This study compared second-generation chimeric antigen receptors (CAR) encoding signaling domains composed of CD28, ICOS, and 4-1BB (TNFRSF9).
more...
No comment yet.
Scooped by Julien Valton
Scoop.it!

Targeting CD20+ Aggressive B-cell Non-Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice

The prognosis is very dismal for patients with relapsed CD20+ B-cell non-Hodgkin lymphoma (B-NHL).
more...
No comment yet.
Scooped by Julien Valton
Scoop.it!

Functional Tuning of CARs Reveals Signaling Threshold above Which CD8+ CTL Antitumor Potency Is Attenuated due to Cell Fas-FasL-Dependent AICD

Chimeric antigen receptor (CAR) development is biased toward selecting constructs that elicit the highest magnitude of T-cell functional outputs.
more...
No comment yet.
Scooped by Julien Valton
Scoop.it!

CD138-directed adoptive immunotherapy of Chimeric Antigen Receptor (CAR)-modified T cells for Multiple Myeloma

AbstractAdoptive immunotherapy with T cells expressing a tumor-associated chimeric antigen receptor (CAR) provides a promising approach for tumor therapy. We designed a clinical trial for multiple myeloma (MM) treatment with CAR-modified T cells recognizing CD138 (CART-138). Five patients diagnosed with chemotherapy-refractory MM were enrolled into this trial, although one later advanced to plasma cell leukemia. By intravenous infusions, these patients received CD3+ CART-138 cells in an escalating dose. No intolerable toxicity was observed during this process. CART-138 cells were expanded to a level 1,000 times higher than the initial engraftment level and were maintained in the peripheral blood. In addition, increased CART-138 cells were also detected in the bone marrow. Four of the five patients had stable disease (SD) longer than three months, and one patient with advanced plasma cell leukemia had a reduction of the myeloma cells in her peripheral blood (from 10.5% to <3%). This study suggests that the treatment of CART-138 is safe, feasible, and tolerable and has potential antitumor activity in vivo, warranting further research in MM treatment using CART-138.
more...
No comment yet.
Scooped by Julien Valton
Scoop.it!

Chimeric antigen receptor T cells for ALL - The Lancet

Chimeric antigen receptor T cells for ALL - The Lancet | Adoptive CAR T Cell Immunotherapy | Scoop.it
Chimeric antigen receptor T cells for ALL http://t.co/DEY0Dn3F9C
more...
No comment yet.
Scooped by Julien Valton
Scoop.it!

Molecular Therapy - Abstract of article: Enhancing anti-tumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression

mt is a cross-disciplinary biomedical journal devoted to publishing the most exciting advances in pharmacology and therapeutics, as they pertain to advances in translational and clinical medicine.
more...
No comment yet.
Scooped by Julien Valton
Scoop.it!

Designing chimeric antigen receptors to effectively and safely targ... - PubMed - NCBI

Curr Opin Immunol. 2015 Jan 23;33C:9-15. doi: 10.1016/j.coi.2015.01.002. [Epub ahead of print] REVIEW
more...
No comment yet.
Scooped by Julien Valton
Scoop.it!

Target Antigen Density Governs the Efficacy of Anti-CD20-CD28-CD3 {zeta} Chimeric Antigen Receptor-Modified Effector CD8+ T Cells [ANTIGEN RECOGNITION AND RESPONSES]

The effectiveness of chimeric Ag receptor (CAR)–transduced T (CAR-T) cells has been attributed to supraphysiological signaling through CARs.
more...
No comment yet.
Rescooped by Julien Valton from Cancer Immunotherapy Review
Scoop.it!

Biopolymer implants enhance the efficacy of adoptive T-cell therapy - Nature.com

Although adoptive T-cell therapy holds promise for the treatment of many cancers, its clinical utility has been limited by problems in delivering targeted lymphocytes to tumor sites, and the cells' inefficient expansion in the immunosuppressive tumor microenvironment. Here we describe a bioactive polymer implant capable of delivering, expanding and dispersing tumor-reactive T cells. The approach can be used to treat inoperable or incompletely removed tumors by situating implants near them or at resection sites. Using a mouse breast cancer resection model, we show that the implants effectively support tumor-targeting T cells throughout resection beds and associated lymph nodes, and reduce tumor relapse compared to conventional delivery modalities. In a multifocal ovarian cancer model, we demonstrate that polymer-delivered T cells trigger regression, whereas injected tumor-reactive lymphocytes have little curative effect. Scaffold-based T-cell delivery may provide a viable treatment option for inoperable tumors and reduce the rate of metastatic relapse after surgery.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, December 17, 2014 3:53 AM

NATURE BIOTECHNOLOGY | RESEARCH | LETTER

Biopolymer implants enhance the efficacy of adoptive T-cell therapySirkka B Stephan,Alexandria M Taber,Ilona Jileaeva,Ericka P Pegues,Charles L Sentman& Matthias T StephanAffiliationsContributionsCorresponding authorNature Biotechnology (2014) doi:10.1038/nbt.3104Received 05 August 2014 Accepted 24 November 2014 Published online 15 December 2014